About CATHAY SECURITIES CORPORATION GLOBAL GENOMICS IMMUNOLOGY & MEDICAL REV

00898 invests in stocks. The fund's major sectors are Health Technology, with 93.41% stocks, and Health Services, with 5.90% of the basket. The assets are mostly located in the North America region.

00898 top holdings are Genscript Biotech Corporation and CRISPR Therapeutics AG, occupying 3.32% and 3.23% of the portfolio correspondingly.

00898 assets under management is ‪1.28 B‬ TWD. It's risen 2.17% over the last month.

00898 fund flows account for ‪−358.64 M‬ TWD (1 year). Many traders use this metric to get insight into investors' sentiment and evaluate whether it's time to buy or sell the fund.

No, 00898 doesn't pay dividends to its holders.

00898 expense ratio is 1.05% meaning you'd have to pay 1.05% of your investment to help manage the fund.

00898 follows the Solactive Global Genomics Immunology and Medical Revolution Index - Benchmark TR Net. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.

00898 invests in stocks.

00898 price has risen by 1.88% over the last month, and its yearly performance shows a −15.82% decrease. See more dynamics on 00898 price chart.
NAV returns, another gauge of an ETF dynamics, showed a −14.59% decrease in three-month performance and has decreased by −16.03% in a year.